article thumbnail

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Pharmaceutical Technology

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Allergies 299
article thumbnail

England witnesses sharp rise in food allergy incidence

Pharmaceutical Technology

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.

Allergies 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xolair amplifies reach after FDA approval for treating food allergies 

Pharmaceutical Technology

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Allergies 236
article thumbnail

UCB to divest China neurology and allergy business for $680m

Pharmaceutical Technology

UCB has entered a divestment agreement in China to sell its mature neurology and allergy business to CBC Group and Mubadala for $680m.

Allergies 130
article thumbnail

Ligelizumab by Novartis for Food Allergy: Likelihood of Approval

Pharmaceutical Technology

Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.

Allergies 187
article thumbnail

Groundbreaking mRNA Therapy Appears To Prevent and Treat Peanut Allergies in Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

More treatments – and faster-acting treatments – for peanut allergies are urgently needed, and a new study outlines a promising drug technology based around a tiny nanoparticle just a few billionths of a meter in size. In tests on mice, the nanoparticle reversed peanut allergies and prevented them from developing in the first place.

Allergies 197
article thumbnail

Food Allergy Awareness Week 2024: How can new treatments target an unmet need?

Pharmaceutical Technology

IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.

Allergies 147